# NCT03290950 (NCT03290950)

> A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03290950
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Multiple Myeloma
- Interventions: daratumumab; carfilzomib; lenalidomide; dexamethasone; dexamethasone
- Enrollment: 69
- Primary outcome: Best Overall Response

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03290950